Levodopa motor complications in Parkinson's disease
Identifieur interne : 000214 ( Istex/Corpus ); précédent : 000213; suivant : 000215Levodopa motor complications in Parkinson's disease
Auteurs : José A. Obeso ; C. Warren Olanow ; John G. NuttSource :
- Trends in Neurosciences [ 0166-2236 ] ; 2000.
Abstract
Parkinson's disease (PD) is an age-related neurodegenerative disorder with an average onset age of 60 years. In the United States, approximately one million persons suffer from PD, and there are 60 000 newly diagnosed cases every year. The estimated cost of PD to society is $27 billion per year. Based on United States Census Bureau projections, it is estimated that the frequency of PD will increase fourfold by the year 2040, making it an even larger burden on patients, their families and society.
Url:
DOI: 10.1016/S1471-1931(00)00031-8
Links to Exploration step
ISTEX:1669EBBA9ACF5CF809C787A4F27B338CBFFDBC0CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa motor complications in Parkinson's disease</title><author><name sortKey="Obeso, Jose A" sort="Obeso, Jose A" uniqKey="Obeso J" first="José A." last="Obeso">José A. Obeso</name><affiliation><mods:affiliation>Movement Disorders and Basal Ganglia Group, Dept of Neurology and Neurosurgery, Neuroscience Center, Clinica Universitaria and Medical School, 31080 Pamplona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Dept of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA</mods:affiliation></affiliation></author><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name><affiliation><mods:affiliation>Dept of Neurology, Oregon Health Sciences University, Portland, OR 97201, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1669EBBA9ACF5CF809C787A4F27B338CBFFDBC0C</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S1471-1931(00)00031-8</idno><idno type="url">https://api.istex.fr/document/1669EBBA9ACF5CF809C787A4F27B338CBFFDBC0C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000214</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000214</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa motor complications in Parkinson's disease</title><author><name sortKey="Obeso, Jose A" sort="Obeso, Jose A" uniqKey="Obeso J" first="José A." last="Obeso">José A. Obeso</name><affiliation><mods:affiliation>Movement Disorders and Basal Ganglia Group, Dept of Neurology and Neurosurgery, Neuroscience Center, Clinica Universitaria and Medical School, 31080 Pamplona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Dept of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA</mods:affiliation></affiliation></author><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name><affiliation><mods:affiliation>Dept of Neurology, Oregon Health Sciences University, Portland, OR 97201, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Trends in Neurosciences</title><title level="j" type="abbrev">TINS</title><idno type="ISSN">0166-2236</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">23</biblScope><biblScope unit="supplement">S1</biblScope><biblScope unit="page" from="S2">S2</biblScope><biblScope unit="page" to="S7">S7</biblScope></imprint><idno type="ISSN">0166-2236</idno></series><idno type="istex">1669EBBA9ACF5CF809C787A4F27B338CBFFDBC0C</idno><idno type="DOI">10.1016/S1471-1931(00)00031-8</idno><idno type="PII">S1471-1931(00)00031-8</idno><idno type="ArticleID">00000318</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0166-2236</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is an age-related neurodegenerative disorder with an average onset age of 60 years. In the United States, approximately one million persons suffer from PD, and there are 60 000 newly diagnosed cases every year. The estimated cost of PD to society is $27 billion per year. Based on United States Census Bureau projections, it is estimated that the frequency of PD will increase fourfold by the year 2040, making it an even larger burden on patients, their families and society.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>José A. Obeso</name><affiliations><json:string>Movement Disorders and Basal Ganglia Group, Dept of Neurology and Neurosurgery, Neuroscience Center, Clinica Universitaria and Medical School, 31080 Pamplona, Spain</json:string></affiliations></json:item><json:item><name>C. Warren Olanow</name><affiliations><json:string>Dept of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA</json:string></affiliations></json:item><json:item><name>John G. Nutt</name><affiliations><json:string>Dept of Neurology, Oregon Health Sciences University, Portland, OR 97201, USA</json:string></affiliations></json:item></author><articleId><json:string>00000318</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>Editorial</json:string></originalGenre><abstract>Parkinson's disease (PD) is an age-related neurodegenerative disorder with an average onset age of 60 years. In the United States, approximately one million persons suffer from PD, and there are 60 000 newly diagnosed cases every year. The estimated cost of PD to society is $27 billion per year. Based on United States Census Bureau projections, it is estimated that the frequency of PD will increase fourfold by the year 2040, making it an even larger burden on patients, their families and society.</abstract><qualityIndicators><score>5.996</score><pdfVersion>1.3</pdfVersion><pdfPageSize>634 x 850 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>501</abstractCharCount><pdfWordCount>5477</pdfWordCount><pdfCharCount>30602</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>83</abstractWordCount></qualityIndicators><title>Levodopa motor complications in Parkinson's disease</title><pii><json:string>S1471-1931(00)00031-8</json:string></pii><genre><json:string>editorial</json:string></genre><serie><volume>44</volume><language><json:string>unknown</json:string></language><title>(Suppl. 1)</title></serie><host><volume>23</volume><pii><json:string>S0166-2236(00)X0239-1</json:string></pii><pages><last>S7</last><first>S2</first></pages><issn><json:string>0166-2236</json:string></issn><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><title>Trends in Neurosciences</title><publicationDate>2000</publicationDate></host><categories><wos><json:string>science</json:string><json:string>neurosciences</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1016/S1471-1931(00)00031-8</json:string></doi><id>1669EBBA9ACF5CF809C787A4F27B338CBFFDBC0C</id><score>0.17574337</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/1669EBBA9ACF5CF809C787A4F27B338CBFFDBC0C/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/1669EBBA9ACF5CF809C787A4F27B338CBFFDBC0C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/1669EBBA9ACF5CF809C787A4F27B338CBFFDBC0C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Levodopa motor complications in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>©2000 Elsevier Science Ltd. All rights reserved.</p></availability><date>2000</date></publicationStmt><notesStmt><note type="content">Section title: Introduction</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Levodopa motor complications in Parkinson's disease</title><author xml:id="author-1"><persName><forename type="first">José A.</forename><surname>Obeso</surname></persName><affiliation>Movement Disorders and Basal Ganglia Group, Dept of Neurology and Neurosurgery, Neuroscience Center, Clinica Universitaria and Medical School, 31080 Pamplona, Spain</affiliation></author><author xml:id="author-2"><persName><forename type="first">C. Warren</forename><surname>Olanow</surname></persName><affiliation>Dept of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA</affiliation></author><author xml:id="author-3"><persName><forename type="first">John G.</forename><surname>Nutt</surname></persName><affiliation>Dept of Neurology, Oregon Health Sciences University, Portland, OR 97201, USA</affiliation></author></analytic><monogr><title level="j">Trends in Neurosciences</title><title level="j" type="abbrev">TINS</title><idno type="pISSN">0166-2236</idno><idno type="PII">S0166-2236(00)X0239-1</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000"></date><biblScope unit="volume">23</biblScope><biblScope unit="supplement">S1</biblScope><biblScope unit="page" from="S2">S2</biblScope><biblScope unit="page" to="S7">S7</biblScope></imprint></monogr><idno type="istex">1669EBBA9ACF5CF809C787A4F27B338CBFFDBC0C</idno><idno type="DOI">10.1016/S1471-1931(00)00031-8</idno><idno type="PII">S1471-1931(00)00031-8</idno><idno type="ArticleID">00000318</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Parkinson's disease (PD) is an age-related neurodegenerative disorder with an average onset age of 60 years. In the United States, approximately one million persons suffer from PD, and there are 60 000 newly diagnosed cases every year. The estimated cost of PD to society is $27 billion per year. Based on United States Census Bureau projections, it is estimated that the frequency of PD will increase fourfold by the year 2040, making it an even larger burden on patients, their families and society.</p></abstract></profileDesc><revisionDesc><change when="2000">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/1669EBBA9ACF5CF809C787A4F27B338CBFFDBC0C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier simple-article found" wicri:toSee="Element simple-tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 5.0.1//EN//XML" URI="art501.dtd" name="istex:docType"></istex:docType><istex:document><simple-article version="5.0" xml:lang="en" docsubtype="edi"><item-info><jid>TINS</jid><aid>00000318</aid><ce:pii>S1471-1931(00)00031-8</ce:pii><ce:doi>10.1016/S1471-1931(00)00031-8</ce:doi><ce:copyright type="unknown" year="2000">Elsevier Science Ltd. All rights reserved.</ce:copyright></item-info><simple-head><ce:dochead><ce:textfn>Introduction</ce:textfn></ce:dochead><ce:title>Levodopa motor complications in Parkinson's disease</ce:title><ce:author-group><ce:author><ce:given-name>José A.</ce:given-name><ce:surname>Obeso</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>C. Warren</ce:given-name><ce:surname>Olanow</ce:surname><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>John G.</ce:given-name><ce:surname>Nutt</ce:surname><ce:cross-ref refid="aff3"><ce:sup>c</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="aff1"><ce:label>a</ce:label><ce:textfn>Movement Disorders and Basal Ganglia Group, Dept of Neurology and Neurosurgery, Neuroscience Center, Clinica Universitaria and Medical School, 31080 Pamplona, Spain</ce:textfn></ce:affiliation><ce:affiliation id="aff2"><ce:label>b</ce:label><ce:textfn>Dept of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff3"><ce:label>c</ce:label><ce:textfn>Dept of Neurology, Oregon Health Sciences University, Portland, OR 97201, USA</ce:textfn></ce:affiliation></ce:author-group><ce:abstract id="ab1" class="author" xml:lang="en"><ce:abstract-sec><ce:simple-para>Parkinson's disease (PD) is an age-related neurodegenerative disorder with an average onset age of 60 years. In the United States, approximately one million persons suffer from PD, and there are 60 000 newly diagnosed cases every year. The estimated cost of PD to society is $27 billion per year. Based on United States Census Bureau projections, it is estimated that the frequency of PD will increase fourfold by the year 2040, making it an even larger burden on patients, their families and society.</ce:simple-para></ce:abstract-sec></ce:abstract></simple-head><simple-tail><ce:bibliography><ce:section-title>Selected references</ce:section-title><ce:bibliography-sec><ce:bib-reference id="bib1"><ce:label>1</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Parkinson</ce:surname><ce:given-name>J.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>An Essay on the Shaking Palsy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:book><sb:date>1817</sb:date><sb:publisher><sb:name>Sherwood</sb:name></sb:publisher></sb:book></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>2</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Olanow</ce:surname><ce:given-name>C.W.</ce:given-name></sb:author><sb:author><ce:surname>Koller</ce:surname><ce:given-name>W.C.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines (American Academy of Neurology)</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurology</sb:maintitle></sb:title><sb:volume-nr>50</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 3</sb:issue-nr><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>57</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>3</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Jellinger</ce:surname><ce:given-name>K.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The pathology of parkinsonism</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:editors><sb:editor><ce:surname>Marsden</ce:surname><ce:given-name>C.D.</ce:given-name></sb:editor><sb:editor><ce:surname>Fahn</ce:surname><ce:given-name>S.</ce:given-name></sb:editor></sb:editors><sb:title><sb:maintitle>Movement Disorders 2</sb:maintitle></sb:title><sb:date>1987</sb:date><sb:publisher><sb:name>Butterworth-Heinemann</sb:name><sb:location>London</sb:location></sb:publisher></sb:edited-book><sb:pages><sb:first-page>124</sb:first-page><sb:last-page>165</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>4</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Kish</ce:surname><ce:given-name>S.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Uneven pattern of dopamine loss in the striatum of patients with Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>New Engl. J. Med.</sb:maintitle></sb:title><sb:volume-nr>318</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>876</sb:first-page><sb:last-page>880</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>5</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Vingerhoets</ce:surname><ce:given-name>F.J.G.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>36</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>759</sb:first-page><sb:last-page>764</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>6</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Cotzias</ce:surname><ce:given-name>G.C.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Aromatic aminoacids and modification of parkinsonism</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>New Engl. J. Med.</sb:maintitle></sb:title><sb:volume-nr>276</sb:volume-nr></sb:series><sb:date>1967</sb:date></sb:issue><sb:pages><sb:first-page>374</sb:first-page><sb:last-page>379</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>7</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Hughes</ce:surname><ce:given-name>A.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurol. Neurosurg. Psychiatry</sb:maintitle></sb:title><sb:volume-nr>55</sb:volume-nr></sb:series><sb:date>1992</sb:date></sb:issue><sb:pages><sb:first-page>181</sb:first-page><sb:last-page>184</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>8</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Marsden</ce:surname><ce:given-name>C.D.</ce:given-name></sb:author><sb:author><ce:surname>Parkes</ce:surname><ce:given-name>J.D.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Success and problems of long-term levodopa therapy in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Lancet</sb:maintitle></sb:title><sb:volume-nr>1</sb:volume-nr></sb:series><sb:date>1977</sb:date></sb:issue><sb:pages><sb:first-page>345</sb:first-page><sb:last-page>349</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>9</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Obeso</ce:surname><ce:given-name>J.A.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Motor complications associated with chronic levodopa therapy in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurology</sb:maintitle></sb:title><sb:volume-nr>39</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 2</sb:issue-nr><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>11</sb:first-page><sb:last-page>19</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>10</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Fénelon</ce:surname><ce:given-name>G.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain</sb:maintitle></sb:title><sb:volume-nr>123</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>733</sb:first-page><sb:last-page>745</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>11</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Hughes</ce:surname><ce:given-name>T.A.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurology</sb:maintitle></sb:title><sb:volume-nr>54</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>1596</sb:first-page><sb:last-page>1602</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>12</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Rodriguez</ce:surname><ce:given-name>M.C.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>44</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>175</sb:first-page><sb:last-page>188</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>13</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Olanow</ce:surname><ce:given-name>C.W.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>A radical hypothesis for neurodegeneration</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Trends Neurosci.</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>1993</sb:date></sb:issue><sb:pages><sb:first-page>439</sb:first-page><sb:last-page>444</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>14</ce:label><sb:reference><sb:comment>(Suppl. 1)</sb:comment><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Olanow</ce:surname><ce:given-name>C.W.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Cell death and neuroprotection in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:book-series><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>44</sb:volume-nr></sb:series></sb:book-series><sb:date>1998</sb:date><sb:publisher><sb:name>Lippincott-Raven</sb:name></sb:publisher></sb:edited-book></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>15</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Benabid</ce:surname><ce:given-name>A.L.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Subthalamic deep brain stimulation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Prog. Neurolog. Surg.</sb:maintitle></sb:title><sb:volume-nr>15</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>196</sb:first-page><sb:last-page>226</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>16</ce:label><ce:other-ref><ce:textref>Olanow, C.W. and Brin, M.F. Surgery for Parkinson's disease: a physician's perspective. <ce:italic>Adv. Neurol.</ce:italic> (in press)</ce:textref></ce:other-ref></ce:bib-reference><ce:bib-reference id="bib17"><ce:label>17</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Olanow</ce:surname><ce:given-name>C.W.</ce:given-name></sb:author><sb:author><ce:surname>Obeso</ce:surname><ce:given-name>J.A.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Preventing levodopa-induced dyskinesias</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>167</sb:first-page><sb:last-page>178</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib18"><ce:label>18</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Grandas</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Risk factors for levodopa-induced dyskinesias in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurol.</sb:maintitle></sb:title><sb:volume-nr>246</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>1127</sb:first-page><sb:last-page>1133</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib19"><ce:label>19</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Colosimo</ce:surname><ce:given-name>C.</ce:given-name></sb:author><sb:author><ce:surname>De Michele</ce:surname><ce:given-name>M.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Motor fluctuations in Parkinson's disease: pathophysiology and treatment</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur. J. Neurol.</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>21</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib20"><ce:label>20</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Marsden</ce:surname><ce:given-name>C.D.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Fluctuations of disability in Parkinson's disease: clinical aspects</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:editors><sb:editor><ce:surname>Marsden</ce:surname><ce:given-name>C.D.</ce:given-name></sb:editor><sb:editor><ce:surname>Fahn</ce:surname><ce:given-name>S.</ce:given-name></sb:editor></sb:editors><sb:title><sb:maintitle>Movement Disorders</sb:maintitle></sb:title><sb:date>1982</sb:date><sb:publisher><sb:name>Butterworth-Heinemann</sb:name></sb:publisher></sb:edited-book><sb:pages><sb:first-page>96</sb:first-page><sb:last-page>119</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib21"><ce:label>21</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Fahn</ce:surname><ce:given-name>S.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Fluctuations of disability in Parkinson's disease: pathophysiology</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:editors><sb:editor><ce:surname>Marsden</ce:surname><ce:given-name>C.D.</ce:given-name></sb:editor><sb:editor><ce:surname>Fahn</ce:surname><ce:given-name>S.</ce:given-name></sb:editor></sb:editors><sb:title><sb:maintitle>Movement Disorders</sb:maintitle></sb:title><sb:date>1982</sb:date><sb:publisher><sb:name>Butterworth-Heinemann</sb:name></sb:publisher></sb:edited-book><sb:pages><sb:first-page>123</sb:first-page><sb:last-page>145</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib22"><ce:label>22</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Quinn</ce:surname><ce:given-name>N.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Young onset Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>73</sb:first-page><sb:last-page>91</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib23"><ce:label>23</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Luquin</ce:surname><ce:given-name>M.R.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:date>1992</sb:date></sb:issue><sb:pages><sb:first-page>117</sb:first-page><sb:last-page>124</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib24"><ce:label>24</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Marconi</ce:surname><ce:given-name>R.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>9</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>2</sb:first-page><sb:last-page>12</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib25"><ce:label>25</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Muenter</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Patterns of dystonia (‘I-D-I’ and ‘D-I-D’) in response to <ce:small-caps>l</ce:small-caps>-dopa therapy for Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:book-series><sb:series><sb:title><sb:maintitle>Mayo Clin. Proc.</sb:maintitle></sb:title><sb:volume-nr>52</sb:volume-nr></sb:series></sb:book-series><sb:date>1977</sb:date></sb:edited-book><sb:pages><sb:first-page>163</sb:first-page><sb:last-page>174</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib26"><ce:label>26</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Fahn</ce:surname><ce:given-name>S.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The spectrum of levodopa-induced dyskinesias</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>3</sb:first-page><sb:last-page>11</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib27"><ce:label>27</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Barbeau</ce:surname><ce:given-name>A.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Long-term side effects of levodopa</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Lancet</sb:maintitle></sb:title><sb:volume-nr>1</sb:volume-nr></sb:series><sb:date>1971</sb:date></sb:issue><sb:pages><sb:first-page>395</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib28"><ce:label>28</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bedard</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Chronic treatment with <ce:small-caps>l</ce:small-caps>-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:title><sb:maintitle>Correlation with [<ce:sup loc="post">3</ce:sup>H]spiperone binding</sb:maintitle></sb:title><sb:book-series><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>379</sb:volume-nr></sb:series></sb:book-series><sb:date>1986</sb:date></sb:edited-book><sb:pages><sb:first-page>294</sb:first-page><sb:last-page>299</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib29"><ce:label>29</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Langston</ce:surname><ce:given-name>W.R.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Chronic parkinsonism in humans due to a product of meperidine analog synthesis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle></sb:title><sb:volume-nr>225</sb:volume-nr></sb:series><sb:date>1984</sb:date></sb:issue><sb:pages><sb:first-page>1480</sb:first-page><sb:last-page>1482</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib30"><ce:label>30</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Nutt</ce:surname><ce:given-name>J.G.</ce:given-name></sb:author><sb:author><ce:surname>Holford</ce:surname><ce:given-name>N.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The response to levodopa in Parkinson's disease: imposing pharmacological law and order</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>39</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>561</sb:first-page><sb:last-page>573</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib31"><ce:label>31</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Quinn</ce:surname><ce:given-name>N.P.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a 4 year period</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>1</sb:volume-nr></sb:series><sb:date>1986</sb:date></sb:issue><sb:pages><sb:first-page>65</sb:first-page><sb:last-page>68</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib32"><ce:label>32</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Hauser</ce:surname><ce:given-name>R.A.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>15</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>485</sb:first-page><sb:last-page>489</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib33"><ce:label>33</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Nutt</ce:surname><ce:given-name>J.G.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Effect of long-term therapy on the pharmacodynamics of levodopa</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:title><sb:maintitle>Relation to on-off phenomenon</sb:maintitle></sb:title><sb:book-series><sb:series><sb:title><sb:maintitle>Arch. Neurol.</sb:maintitle></sb:title><sb:volume-nr>49</sb:volume-nr></sb:series></sb:book-series><sb:date>1992</sb:date></sb:edited-book><sb:pages><sb:first-page>1123</sb:first-page><sb:last-page>1130</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib34"><ce:label>34</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Fabbrini</ce:surname><ce:given-name>G.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>370</sb:first-page><sb:last-page>376</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib35"><ce:label>35</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Mouridian</ce:surname><ce:given-name>M.M.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>22</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>475</sb:first-page><sb:last-page>479</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib36"><ce:label>36</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Chase</ce:surname><ce:given-name>T.N.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Adv. Neurol.</sb:maintitle></sb:title><sb:volume-nr>45</sb:volume-nr></sb:series><sb:date>1986</sb:date></sb:issue><sb:pages><sb:first-page>477</sb:first-page><sb:last-page>480</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib37"><ce:label>37</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Papa</ce:surname><ce:given-name>S.M.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Motor fluctuations in levodopa-treated parkinsonian rats: relation to lesion extent and treatment duration</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>662</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>69</sb:first-page><sb:last-page>74</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib38"><ce:label>38</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Chase</ce:surname><ce:given-name>T.N.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Rationale for continuous dopaminomimetic therapy of Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurology</sb:maintitle></sb:title><sb:volume-nr>39</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 2</sb:issue-nr><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>7</sb:first-page><sb:last-page>10</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib39"><ce:label>39</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Rodriguez</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Motor response to apomorphine and levodopa in asymmetric Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurol. Neurosurg. Psychiatry</sb:maintitle></sb:title><sb:volume-nr>57</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>562</sb:first-page><sb:last-page>566</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib40"><ce:label>40</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Grandas</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Difference in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin. Neuropharmacol.</sb:maintitle></sb:title><sb:volume-nr>15</sb:volume-nr></sb:series><sb:date>1992</sb:date></sb:issue><sb:pages><sb:first-page>13</sb:first-page><sb:last-page>18</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib41"><ce:label>41</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Colosimo</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurol. Neurosurg. Psychiatry</sb:maintitle></sb:title><sb:volume-nr>60</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>634</sb:first-page><sb:last-page>637</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib42"><ce:label>42</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bravi</ce:surname><ce:given-name>D.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>36</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>27</sb:first-page><sb:last-page>31</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib43"><ce:label>43</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Nutt</ce:surname><ce:given-name>J.G.</ce:given-name></sb:author><sb:author><ce:surname>Carter</ce:surname><ce:given-name>J.H.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Apomorphine can sustain the long-duration response to <ce:small-caps>l</ce:small-caps>-DOPA in fluctuating Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurology</sb:maintitle></sb:title><sb:volume-nr>54</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>247</sb:first-page><sb:last-page>250</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib44"><ce:label>44</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Limousin</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>New Engl. J. Med.</sb:maintitle></sb:title><sb:volume-nr>339</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>1105</sb:first-page><sb:last-page>1111</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib45"><ce:label>45</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Linazasoro</ce:surname><ce:given-name>G.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Deep brain stimulation changes the magnitude of the motor response to levodopa in Parkinson's disease: pathophysiological implications</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Soc. Neurosci. Abstr.</sb:maintitle></sb:title><sb:volume-nr>25</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>1013</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib46"><ce:label>46</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bejjani</ce:surname><ce:given-name>B.P.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>655</sb:first-page><sb:last-page>658</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib47"><ce:label>47</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Lang</ce:surname><ce:given-name>A.E.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Posteroventral medial pallidotomy in advanced Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>New Engl. J. Med.</sb:maintitle></sb:title><sb:volume-nr>337</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>1036</sb:first-page><sb:last-page>1042</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib48"><ce:label>48</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Crossman</ce:surname><ce:given-name>A.R.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>A hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist-induced dyskinesia in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>5</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>100</sb:first-page><sb:last-page>108</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib49"><ce:label>49</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Delong</ce:surname><ce:given-name>M.R.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Primate models of movement disorders of basal ganglia origin</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Trends Neurosci.</sb:maintitle></sb:title><sb:volume-nr>13</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>281</sb:first-page><sb:last-page>285</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib50"><ce:label>50</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Obeso</ce:surname><ce:given-name>J.A.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>22</sb:first-page><sb:last-page>34</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib51"><ce:label>51</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Calon</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Molecular basis of levodopa-induced dyskinesias</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>70</sb:first-page><sb:last-page>78</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib52"><ce:label>52</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Obeso</ce:surname><ce:given-name>J.A.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur. J. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>889</sb:first-page><sb:last-page>897</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib53"><ce:label>53</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Brotchie</ce:surname><ce:given-name>J.M.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The neural mechanisms underlying levodopainduced dyskinesia in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>105</sb:first-page><sb:last-page>114</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib54"><ce:label>54</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Gerfen</ce:surname><ce:given-name>C.R.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Dopamine-mediated gene regulation in models of Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>42</sb:first-page><sb:last-page>50</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib55"><ce:label>55</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Chase</ce:surname><ce:given-name>T.N.</ce:given-name></sb:author><sb:author><ce:surname>Oh</ce:surname><ce:given-name>J.D.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Striatal mechanisms and pathogenesis of parkinsonian signs</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>122</sb:first-page><sb:last-page>130</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib56"><ce:label>56</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Calabresi</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Trends Neurosci.</sb:maintitle></sb:title><sb:volume-nr>19</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>19</sb:first-page><sb:last-page>24</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib57"><ce:label>57</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Jenner</ce:surname><ce:given-name>P.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Factors influencing the onset and persistence of dyskinesias in the parkinsonian primate</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>S90</sb:first-page><sb:last-page>S104</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib58"><ce:label>58</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Henry</ce:surname><ce:given-name>B.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Effect of repeated <ce:small-caps>l</ce:small-caps>-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Exp. Neurol.</sb:maintitle></sb:title><sb:volume-nr>155</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>204</sb:first-page><sb:last-page>220</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib59"><ce:label>59</ce:label><sb:reference><sb:comment>(Suppl.)</sb:comment><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Obeso</ce:surname><ce:given-name>J.A.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Continuous dopaminergic stimulation for Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neural Transm.</sb:maintitle></sb:title><sb:volume-nr>27</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>249</sb:first-page><sb:last-page>252</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib60"><ce:label>60</ce:label><sb:reference><sb:comment>(Suppl. <ce:italic>Basal ganglia, Parkinson's disease and levodopa therapy</ce:italic>)</sb:comment><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Olanow</ce:surname><ce:given-name>C.W.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Continuous dopaminergic-receptor stimulation in early Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Trends Neurosci.</sb:maintitle></sb:title><sb:volume-nr>23</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>S117</sb:first-page><sb:last-page>S126</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib61"><ce:label>61</ce:label><sb:reference><sb:comment>056 Study Group</sb:comment><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Rascol</ce:surname><ce:given-name>O.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>New Engl. J. Med.</sb:maintitle></sb:title><sb:volume-nr>342</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>1484</sb:first-page><sb:last-page>1491</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></simple-tail></simple-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Levodopa motor complications in Parkinson's disease</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Levodopa motor complications in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">José A.</namePart><namePart type="family">Obeso</namePart><affiliation>Movement Disorders and Basal Ganglia Group, Dept of Neurology and Neurosurgery, Neuroscience Center, Clinica Universitaria and Medical School, 31080 Pamplona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. Warren</namePart><namePart type="family">Olanow</namePart><affiliation>Dept of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">John G.</namePart><namePart type="family">Nutt</namePart><affiliation>Dept of Neurology, Oregon Health Sciences University, Portland, OR 97201, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="editorial" displayLabel="Editorial"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2000</dateIssued><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Parkinson's disease (PD) is an age-related neurodegenerative disorder with an average onset age of 60 years. In the United States, approximately one million persons suffer from PD, and there are 60 000 newly diagnosed cases every year. The estimated cost of PD to society is $27 billion per year. Based on United States Census Bureau projections, it is estimated that the frequency of PD will increase fourfold by the year 2040, making it an even larger burden on patients, their families and society.</abstract><note type="content">Section title: Introduction</note><relatedItem type="host"><titleInfo><title>Trends in Neurosciences</title></titleInfo><titleInfo type="abbreviated"><title>TINS</title></titleInfo><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">200010</dateIssued></originInfo><identifier type="ISSN">0166-2236</identifier><identifier type="PII">S0166-2236(00)X0239-1</identifier><part><date>200010</date><detail type="volume"><number>23</number><caption>vol.</caption></detail><detail type="supplement"><number>S1</number><caption>Suppl.</caption></detail><extent unit="issue pages"><start>S1</start><end>S126</end></extent><extent unit="pages"><start>S2</start><end>S7</end></extent></part></relatedItem><identifier type="istex">1669EBBA9ACF5CF809C787A4F27B338CBFFDBC0C</identifier><identifier type="DOI">10.1016/S1471-1931(00)00031-8</identifier><identifier type="PII">S1471-1931(00)00031-8</identifier><identifier type="ArticleID">00000318</identifier><accessCondition type="use and reproduction" contentType="copyright">©2000 Elsevier Science Ltd. All rights reserved.</accessCondition><recordInfo><recordContentSource>ELSEVIER</recordContentSource><recordOrigin>Elsevier Science Ltd. All rights reserved., ©2000</recordOrigin></recordInfo></mods></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/DanceTherParkinsonV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000214 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000214 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= DanceTherParkinsonV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1669EBBA9ACF5CF809C787A4F27B338CBFFDBC0C
|texte= Levodopa motor complications in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.35. |  |